Bond Avillion 2 Development LP

6 clinical trials · Sponsor

Record	Firm	Date
A Comparison of PT027 vs PT007 Used as Needed in Participants With Asthma (NCT05505734)	Bond Avillion 2 Development LP	2022-09-02
To Compare the Pharmacokinetics of Budesonide Delivered by BDA MDI to Budesonide Delivered by Pulmicort Respules in Children With Asthma Aged 4 to 8 Years. (NCT04848662)	Bond Avillion 2 Development LP	2021-05-06
A Study to Assess the Efficacy of Budesonide/Albuterol Metered-dose Inhaler (BDA MDI/PT027) on Exercise-induced Bronchoconstriction in Adults and Adolescents With Asthma (NCT04234464)	Bond Avillion 2 Development LP	2020-01-15
A Study to Assess the Efficacy and Safety of Budesonide/Albuterol Metered Dose Inhaler (BDA MDI/PT027) Used 4 Times Daily in Adults and Children 4 Years of Age or Older With Asthma (NCT03847896)	Bond Avillion 2 Development LP	2019-03-20
A Study to Assess the Efficacy and Safety of Budesonide/Albuterol Metered-dose Inhaler (BDA MDI/PT027) in Adults and Children 4 Years of Age or Older With Asthma (NCT03769090)	Bond Avillion 2 Development LP	2018-12-13
A Phase 2b Study of the Efficacy, Safety, and Tolerability of M1095 (Sonelokimab) in Subjects With Moderate to Severe Psoriasis (NCT03384745)	Bond Avillion 2 Development LP	2018-07-31

Every clearance here is in the API, with alerts when new ones post.